Table 2.
Characteristics of patients ≥ 18 years receiving matched unrelated donor transplants for CML in first chronic phase, reported to the CIBMTR, 1990–2004.
| Non Smokers | Smokers |
|||||
|---|---|---|---|---|---|---|
| Low dosea | High dosea | |||||
| Variables | N | N (%) | N | N (%) | N | N (%) |
| Number of patients | 544 | 131 | 30 | |||
| Age at transplant, years, median (range) | 544 | 34 (18–61) | 131 | 37 (19–58) | 30 | 43 (19–53) |
| Age at transplant, years | 544 | 131 | 30 | |||
| 18 – 29 | 165 (30) | 30 (23) | 2 (7) | |||
| 30 – 39 | 214 (39) | 46 (35) | 8 (27) | |||
| 40 – 49 | 145 (27) | 45 (34) | 15 (50) | |||
| ≥50 | 20 (4) | 10 (8) | 5 (17) | |||
| Male | 544 | 317 (58) | 131 | 89 (68) | 30 | 24 (80) |
| Region | 544 | 131 | 30 | |||
| United States | 173 (32) | 52 (40) | 19 (63) | |||
| Canada | 31 (6) | 8 (6) | 2 (7) | |||
| Europe | 245 (45) | 56 (43) | 7 (23) | |||
| Asia | 54 (10) | 13 (10) | 1 (3) | |||
| Australia/New Zealand | 20 (4) | 1 (1) | 0 (0) | |||
| Mideast/Africa | 8 (1) | 0 (0) | 0 (0) | |||
| Central/South America | 13 (2) | 1 (1) | 1 (3) | |||
| Karnofsky score (< 90%) | 535 | 49 (9) | 131 | 11 (8) | 30 | 5 (17) |
| Number of packs per day | 131 | 30 | ||||
| ≤1 | -- | 131 (100) | -- | |||
| > 1 | -- | -- | 30 (100) | |||
| Number of years smoked, median (range) | -- | 131 | 15 (2–35) | 30 | 20 (6–35) | |
| Smoking pack-year, median (range) | -- | 131 | 10 (1–35) | 30 | 35 (12–93) | |
| Smoking pack-year | 131 | 30 | ||||
| ≤10 pack-year | -- | 66 (50) | -- | |||
| > 10 pack-year | -- | 65 (50) | 30 (100) | |||
| Body mass index, kg/m2 | 535 | 126 | 30 | |||
| ≤22 | 116 (22) | 31 (25) | 5 (17) | |||
| 22–30 | 338 (63) | 73 (58) | 17 (57) | |||
| > 30 | 81 (15) | 22 (17) | 8 (27) | |||
| White cell count at diagnosis, 109/L, median (range) | 487 | 150 (4–790) | 115 | 126 (1–779) | 30 | 116 (19–334) |
| White cell count at diagnosis, 109/L | 487 | 115 | 30 | |||
| < 50 | 84 (17) | 34 (30) | 6 (20) | |||
| 50 – 100 | 83 (17) | 17 (15) | 7 (23) | |||
| > 100 | 320 (66) | 64 (56) | 17 (57) | |||
| Spleen size at diagnosis | 452 | 108 | 26 | |||
| Normal | 147 (33) | 53 (49) | 9 (35) | |||
| Enlarged | 305 (67) | 55 (51) | 17 (65) | |||
| Coexisting diseases | 543 | 131 | 30 | |||
| Cardiac and Pulmonary | 3 (1) | 0 (0) | 0 (0) | |||
| Cardiac | 26 (5) | 8 (6) | 5 (17) | |||
| Pulmonary | 9 (2) | 3 (2) | 3 (10) | |||
| Other | 78 (14) | 18 (14) | 5 (17) | |||
| None | 427 (79) | 102 (78) | 17 (57) | |||
| Pre-transplant therapy for CML | ||||||
| Hydroxyurea | 538 | 507 (94) | 130 | 114 (88) | 30 | 24 (80) |
| Interferon | 479 | 308 (64) | 118 | 86 (73) | 25 | 17 (68) |
| Imatinib | 543 | 48 (9) | 131 | 5 (4) | 30 | 0 (0) |
| Time from diagnosis to transplant, months, median (range) | 544 | 15 (1–111) | 131 | 16 (3–95) | 30 | 17 (6–39) |
| Time from diagnosis to transplant, months | 544 | 131 | 30 | |||
| < 6 | 50 (9) | 6 (5) | 0 (0) | |||
| 6 – 11 | 145 (27) | 38 (29) | 11 (37) | |||
| 12 – 23 | 180 (33) | 54 (41) | 14 (47) | |||
| ≥24 | 169 (31) | 33 (25) | 5 (17) | |||
| EBMT Risk Score | 526 | 122 | 28 | |||
| 0–1 | 10 (2) | 0 (0) | 1 (4) | |||
| 2 | 130 (25) | 21 (17) | 0 (0) | |||
| 3 | 226 (43) | 52 (43) | 12 (43) | |||
| 4 | 144 (27) | 42 (34) | 12 (43) | |||
| 5 | 16 (3) | 7 (6) | 3 (11) | |||
| Year of transplant | 544 | 131 | 30 | |||
| 1990 – 1994 | 192 (35) | 59 (45) | 17 (57) | |||
| 1995 – 1999 | 228 (42) | 57 (44) | 13 (43) | |||
| 2000 – 2004 | 124 (23) | 15 (11) | 0 (0) | |||
| Conditioning regimen | 544 | 131 | 30 | |||
| TBI/Cy ± other | 409 (75) | 100 (76) | 26 (87) | |||
| Bu/Cy ± other (no TBI) | 135 (25) | 31 (24) | 4 (13) | |||
| Degree of matching | 538 | 130 | 29 | |||
| Well Matched | 68 (13) | 19 (15) | 5 (17) | |||
| Partially matched | 162 (30) | 40 (31) | 13 (45) | |||
| Mismatched | 211 (39) | 57 (44) | 9 (31) | |||
| Unknown | 97 (18) | 14 (11) | 2 (7) | |||
| Dose of Cyb, mg/kg | 466 | 107 | 23 | |||
| 120 | 415 (89) | 93 (87) | 21 (91) | |||
| 200 | 51 (11) | 14 (13) | 2 (9) | |||
| Dose of Bu, mg/kg | 542 | 129 | 30 | |||
| No Bu | 409 (75) | 100 (78) | 26 (87) | |||
| < 12 | 13 (2) | 0 (0) | 0 (0) | |||
| 12–16 | 28 (5) | 6 (5) | 0 (0) | |||
| 16–17 | 85 (16) | 21 (16) | 3 (10) | |||
| ≥17 | 7 (1) | 2 (2) | 1 (3) | |||
| Dose of TBI, cGy | 523 | 124 | 29 | |||
| Non-TBI | 135 (26) | 31 (25) | 4 (14) | |||
| <1300 | 251 (48) | 65 (52) | 13 (45) | |||
| ≥1300 | 137 (26) | 28 (23) | 12 (41) | |||
| GVHD prophylaxis | 544 | 131 | 30 | |||
| T depl ± other | 117 (22) | 29 (22) | 7 (23) | |||
| FK506 ± other | 67 (12) | 10 (8) | 3 (10) | |||
| MTX + CsA ± other | 344 (63) | 87 (66) | 19 (63) | |||
| CsA ± other (no MTX) | 16 (3) | 5 (4) | 1 (3) | |||
| Donor age | 465 | 105 | 24 | |||
| ≤29 | 132 (28) | 20 (19) | 6 (25) | |||
| 30 – 39 | 180 (39) | 54 (51) | 10 (42) | |||
| 40 – 49 | 134 (29) | 26 (25) | 5 (21) | |||
| ≥50 | 19 (4) | 5 (5) | 3 (13) | |||
| Gender match | 532 | 124 | 28 | |||
| Male into male | 213 (40) | 57 (46) | 12 (43) | |||
| Male into female | 122 (23) | 30 (24) | 3 (11) | |||
| Female into male | 97 (18) | 26 (21) | 10 (36) | |||
| Female into female | 100 (19) | 11 (9) | 3 (11) | |||
| Donor-Recipient CMV status | 513 | 121 | 26 | |||
| −/− | 183 (36) | 39 (32) | 9 (35) | |||
| −/+ | 116 (23) | 40 (33) | 4 (15) | |||
| +/− | 81 (16) | 11 (9) | 4 (15) | |||
| +/+ | 133 (26) | 31 (26) | 9 (35) | |||
| Graft type | 544 | 131 | 30 | |||
| BM | 505 (93) | 127 (97) | 29 (97) | |||
| PB ± BM | 39 (7) | 4 (3) | 1 (3) | |||
| Use of ATG or Campath | 505 | 172 (34) | 121 | 33 (27) | 28 | 8 (29) |
| Lung shielding in radiation therapy | 505 | 170 (34) | 119 | 43 (36) | 29 | 13 (45) |
| Follow-up of surviving patients, months | 544 | 79 (4–194) | 131 | 90 (4–195) | 30 | 109 (13–157) |
Abbreviations: CML = chronic myelogenous leukemia; TBI = total body irradiation; Cy = cyclophosphamide; Bu = busulfan; GVHD = graft-versus-host disease; MTX = methotrexate; CsA = cyclosporine; BM=Bone marrow; PB=Peripheral blood.
a
Low dose smokers=smoking ≤ 10 pack-years or > 10 pack-years with 1 ≤ pack/day; high dose smokers=smoking ≥ 10 pack-years with > 1 pack/day.
b
Cy dose range 100–150 mg/kg classified as 120 mg/kg, Cy dose ≥ 150 mg/kg classified as 200 mg/kg.
Duration of follow-up:
Non-smoker: ≥ 1 year = 55%; ≥ 3 year = 43%; ≥ 5 year = 31%.
Low dose smoker: ≥ 1 year = 53%; ≥ 3 year = 41%; ≥ 5 year = 33%.
High dose smoker: ≥ 1 year = 54%; ≥ 3 year = 34%; ≥ 5 year = 27%.